Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Jul 2021
Randomized Controlled Trial Multicenter StudyBaricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
Baricitinib, an oral selective Janus kinase 1/Janus kinase 2 inhibitor, is being studied for moderate-to-severe atopic dermatitis (AD) in adults. ⋯ Baricitinib was efficacious for patients with moderate-to-severe AD with no new safety findings over 16 weeks.
-
J. Am. Acad. Dermatol. · May 2021
Practice GuidelineNational Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.
To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic. ⋯ These statements provide guidance for the treatment of patients with psoriatic disease on topics including how the disease and its treatments affect COVID-19 risk, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 (including novel vaccination), and what they should do if they develop COVID-19. The guidance is a living document that is continuously updated by the TF as data emerge.